Evidence map›Paper›PMID 42643586›Full record

ArticleFrontiers in pharmacology2026

Mass balance, excretion, and pharmacokinetics of a single oral dose of [

Chunyang Zhao, Ying Yang, Gangyi Liu, Lin Qian, Yun Liu, Cheng-Yuan Tsai, Li-Wen Chang, Qian Chen, Hongjie Qian, Jingying Jia and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chunyang Zhao *Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China.
Ying Yang *Joincare Pharmaceutical Group Industry Co., Ltd., Shenzhen, Guangdong, China.
Gangyi Liu *Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China.
Lin QianDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China.
Yun LiuDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China.
Cheng-Yuan TsaiTaiGen Biotechnology Co., Ltd., Taipei, Taiwan.
Li-Wen ChangTaiGen Biotechnology Co., Ltd., Taipei, Taiwan.
Qian ChenDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China.
Hongjie QianDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China.
Jingying JiaDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China.
Yanmei LiuDrug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objective: Cap-dependent endonuclease (CEN) inhibitors are a promising novel class of antiviral agents for influenza treatment. This phase I study aimed to evaluate the mass balance, excretion pathways, and pharmacokinetics of pixavir marboxil (TG-1000), a novel CEN inhibitor prodrug, in healthy humans. Methods: Six healthy Chinese male participants received a single oral dose of 40 mg (100 μCi) [ Results: Intact pixavir marboxil was undetectable in plasma. Systemic exposure primarily consisted of its active metabolite, pixavir (TG-0527), and a subsequent glucuronide conjugate, TG-0600771. The geometric mean areas under the curve ( Conclusion: Pixavir marboxil exhibits a favorable pharmacokinetic profile characterized by rapid systemic conversion to its active metabolite, CYP-independent metabolism, and predominantly non-renal clearance. These favorable pharmacokinetic characteristics support a well-characterized disposition profile with limited reliance on CYP-mediated metabolism and renal excretion of active pixavir. Trial Registration: This study was registered with Drug Clinical Trial Registration and Information Disclosure Platform, National Medical Products Administration (NMPA), number CTR20231822 (http://www.chinadrugtrials.org.cn/).

Indexed as

cap-dependent endonuclease inhibitorexcretionhealthy participantsmass balancemetabolite identificationpharmacokineticspixavir marboxilTG-1000

Identifiers

PMID42643586
PMCPMC13503549

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.